Lilly’s Oral Pivot: Foundayo’s Maintenance Data Isn’t a Scientific Win — It’s a Market Access Weapon
Lilly's ATTAIN-MAINTAIN trial shows Foundayo maintains weight loss after injectable GLP-1s — a $42B market's access problem just found...
obesity pipeline